WhitTier Trust Company’s Sarepta Therapeutics SRPT Stock Holding History

WhitTier Trust Company’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$198	Hold	10	–	–	﹤0.01%	1396
2026 Q1	$228	Hold	10	–	–	﹤0.01%	1384
2025 Q4	$224	Hold	10	–	–	﹤0.01%	1254
2025 Q3	$226	Sell	10 -23	-70%	-$410	﹤0.01%	1252
2025 Q2	$563	Sell	33 -166	-83%	-$7.08K	﹤0.01%	1386
2025 Q1	$12.7K	Hold	199	–	–	﹤0.01%	1069
2024 Q4	$24.2K	Sell	199 -1	-0.5%	-$123	﹤0.01%	902
2024 Q3	$25K	Hold	200	–	–	﹤0.01%	898
2024 Q2	$31.6K	Hold	200	–	–	﹤0.01%	792
2024 Q1	$25.9K	Hold	200	–	–	﹤0.01%	810
2023 Q4	$19.3K	Hold	200	–	–	﹤0.01%	848
2023 Q3	$24.2K	Buy	200 +4	+2%	+$452	﹤0.01%	784
2023 Q2	$22.4K	Buy	196 +20	+11%	+$2.58K	﹤0.01%	838
2023 Q1	$24.3K	Buy	176 +10	+6%	+$1.3K	﹤0.01%	812
2022 Q4	$21.5K	Buy	+166	New	+$19.2K	﹤0.01%	831

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WhitTier Trust Company's SRPT Position: Q2 2026 in Review

WhitTier Trust Company held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 10 shares worth $198. The position accounts for ﹤0.01% of the portfolio, ranked #1396.

WhitTier Trust Company first reported a position in SRPT in Q4 2022 and has held it in 15 quarters since. The position peaked at $31.6K in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

WhitTier Trust Company held 10 shares of Sarepta Therapeutics worth $198 as of Q2 2026.
WhitTier Trust Company left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of WhitTier Trust Company's portfolio in Q2 2026, its #1396 holding.
WhitTier Trust Company first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 15 quarters since.
WhitTier Trust Company's Sarepta Therapeutics position peaked at $31.6K in Q2 2024.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.